Clinical trial / 2003
Oral L-arginine supplementation improved flow-mediated dilation and normalized the L-arginine/ADMA ratio in healthy adults over 70 years old.
Twelve healthy older adults (aged 73.8 +/- 2.7 years) received oral L-arginine (8 g twice daily) or placebo for 14 days each in a randomized crossover trial separated by a 14-day washout. L-Arginine significantly improved brachial flow-mediated dilation to 5.7 +/- 1.2% (p < 0.0001), whereas placebo showed no significant effect (-0.25 +/- 0.7%). Plasma L-arginine levels increased from 57.4 +/- 5.0 to 114.9 +/- 11.6 micromol/l after L-arginine supplementation. ADMA levels were elevated at baseline compared to middle-aged individuals (3.9 +/- 0.2 vs. 1.0 +/- 0.1 micromol/l; p < 0.0001) and remained unchanged, but L-arginine normalized the L-arginine/ADMA ratio (p < 0.05).
- Study type
- Double-blind, randomized crossover trial
- Who was studied
- 12 healthy old subjects (age 73.8 +/- 2.7 years)
- What was measured
- Flow-mediated dilation (FMD) of the brachial artery, plasma L-arginine, and ADMA
THE PAPER
Oral L-arginine improves endothelial function in healthy individuals older than 70 years.
Bode-Böger SM, Muke J, Surdacki A, Brabant G, Böger RH, Frölich JC. Vasc Med, 2003.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.